Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-11-04
Target enrollment:
Participant gender:
Summary
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent
of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have
extensive stage (ES-SCLC) at the time of diagnosis, with extremely poor prognosis. However,
the overall survival (OS) of ES-SCLC patients was not significantly prolonged, with platinum
combined with etoposide chemotherapy as the standard treatment. In recent years, the
emergence of Immune checkpoint inhibitor (ICI) has made the treatment of ES-SCLC appear at
the dawn. In Impower133 study, Atezolizumab combined with chemotherapy significantly
prolonged OS(median OS 12.3 months vs 10.3 months, HR=0.70, 95%CI 0.54-0.91, P = 0.007).
Durvalumab combined with chemotherapy (CASPIAN study) is the first study in 20 years in which
the total survival time of ES-SCLC treated by first-line therapy is 13 months, and there is
no significant increase in adverse reactions compared with chemotherapy. Therefore, in 2019,
NCCN also recommended Atezolizumab or Durvalumab+ EC regimens as a category 1 preferred
option for first-line treatment of ES-SCLC.